Opinion|Videos|September 30, 2024
Safety and Efficacy of HER2-Directed ADCs for NSCLC
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
- What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
- How do real-world patient outcomes compare with those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency
2
Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis
3
From Biologics to Bio-Machines: Top Takeaways From Maui Derm 2026
4
The Orphan Drug Act in the Modern Drug Pricing Era
5
